NHS Cervical Screening Programme: Implementing HPV Triage for Women With Mild or Borderline Cervical Screening Test Results and HPV Test of Cure

Objectives

Implement human papillomavirus (HPV) testing throughout the National Health Service Cervical Screening Programme in England as triage for women with borderline or mild cytology results and as a test of cure following treatment for cervical intraepithelial neoplasia (CIN).[1][2]The programme aims to deliver a more patient-centred screening pathway, safely reduce unnecessary repeat cytology and accelerate return to routine recall for women at low risk, while achieving quality, productivity and cost benefits.[1][2][3]

• Introduce HPV triage locally during 2011/12, subject to agreed quality and safety criteria.[3]
• Introduce HPV test of cure during 2012/13, rather than implementing both changes simultaneously where this could compromise quality, safety or colposcopy capacity.[3]
• Use high-risk HPV testing to identify women with borderline or mild screening abnormalities who need immediate colposcopy, while returning HPV-negative women to routine screening.[1][2]
• Use HPV testing six months after CIN treatment for women with negative, borderline or mild cytology, returning HPV-negative women to routine recall and referring those with high-grade cytology or high-risk HPV positivity to colposcopy.[2]
• Develop local clinical and laboratory pathways, maintain adequate colposcopy capacity and align delivery with national cervical screening requirements.[4]
• Achieve timely reporting, with 98% of women receiving their cervical screening result within 14 days.[5][6]

Implementation

Deliver implementation through coordinated local cervical screening networks, supported by NHS Cancer Screening Programmes, strategic health authorities, primary care trusts, primary care services, laboratories, call and recall offices, colposcopy clinics and regional quality-assurance arrangements.[1][5]Local services should submit implementation proposals and establish identifiable pathways led by an appointed pathway manager.[5][4]Implementation funding is managed through NHS Cancer Screening Programmes in 2011/12 and 2012/13 and follows eligible activity from general practice, community, hospital and genitourinary medicine clinics.[4]

• Commission implementation jointly with local services and NHS Cancer Screening Programmes, using national guidance and support packs to standardise delivery.[1][3][4]
• Establish networks connecting call and recall offices, laboratories and colposcopy clinics, with clear pathway-management responsibilities.[5]
• Ensure laboratories process ideally at least 35,000 samples annually, or have credible plans to attain that volume.[5]
• Select HPV testing kits through the NHS Supply Chain Framework Agreement, update laboratory codes and local protocols, and synchronise call and recall systems.[4]
• Train laboratory and clinical staff, educate primary care sample takers and use national template patient letters and materials.[4]
• Maintain sustainable colposcopy and histology capacity, including independent-sector support where needed.[5][4]
• Maintain HPV testing quality, participate in External Quality Assurance and obtain sign-off from the Regional Quality Assurance team and the relevant Primary Care Trust, Primary Care Trust Cluster or emerging Clinical Commissioning Group.[5]
• Use pilot evidence to guide service redesign, recognising that HPV triage reduced repeat cytology and shortened time to routine recall but increased colposcopy referrals.[1][2]
• Monitor HPV status, cytology outcomes, colposcopy referrals, routine-recall returns and compliance with the 14-day reporting standard.[1][2][5][6]
• Fund laboratory costs, test kits, training and additional colposcopy and histology activity; first-year funding was £2 per eligible sample and £100,000 per 50,000 samples from women aged 25 and over, reducing to £1 per eligible sample in 2012/13.[4]
• Plan for higher initial costs while old and new protocols run concurrently and staff are trained, with anticipated net savings of up to £16 million annually thereafter.[3][4]

Monitoring & Evaluation

Implementation is monitored primarily through service quality, laboratory assurance, screening-result timeliness and pathway outcomes for human papillomavirus (HPV) triage and test of cure.[1][2][5][6]

• Track HPV status, cytology results, colposcopy referrals and return to routine recall as operational outcomes of triage and test-of-cure pathways.[1][2]
• Assess clinical effectiveness using evidence that high-risk HPV testing identifies women who may require treatment and that women who are HPV-negative six months after treatment for cervical intraepithelial neoplasia have a very low risk of residual disease.[2]
• Use evidence from six sentinel sites, where HPV triage enabled approximately one-third of women with borderline or mildly dyskaryotic cytology to return directly to routine recall, reducing cytology-service pressure.[3]
• Monitor the test-of-cure pathway, which enabled most HPV-negative women to return directly to routine recall despite having a low positive predictive value for high-grade cervical intraepithelial neoplasia.[3]
• Maintain HPV testing quality, participate in External Quality Assurance, and secure sign-off from the Regional Quality Assurance team and the relevant Primary Care Trust, Primary Care Trust Cluster or emerging Clinical Commissioning Group.[5]
• Meet the operating standard for 98% of women to receive cervical screening results within 14 days.[5][6]
• Oversee local delivery through identifiable screening networks linking call-and-recall offices, colposcopy clinics and laboratories, each with an appointed pathway manager.[5]
• Use local reporting systems, revised national operational and quality-assurance guidance, and support from Regional Quality Assurance Directors.[4][6]

The available material does not specify a comprehensive monitoring framework, routine reporting cycle, wider surveillance system, formal outcome-indicator set, or accountability arrangements beyond quality assurance, commissioning approval and the 14-day reporting requirement.[2][4][6]

Costing & Financing

Implementation of HPV triage and test of cure required central, activity-linked funding for initial delivery costs, but was expected to generate substantial longer-term savings through productivity improvements and reduced cytology workload.[3][4]

• Provide central funding in 2011/12, with funding expected in 2012/13, to help meet additional up-front costs compared with the existing cervical screening programme.[3]
• Manage implementation funding through NHS Cancer Screening Programmes, with funding following activity for eligible samples from general practice and community clinics, hospital services and genitourinary medicine clinics.[4]
• Exclude samples from women aged under 25 and non-NHS samples from this activity-linked implementation funding.[4]
• Cover laboratory costs, HPV test kits, training, and increased colposcopy and histology activity through implementation funding.[4]
• Recognise higher first-year costs because old and new protocols operate concurrently and staff training is required.[4]
• Anticipate quality and productivity gains of around 16 million Pounds sterling annually by the third year of roll-out from 2013/14, with the investment also expected to yield net savings of up to 16 million Pounds sterling per annum thereafter.[3][4]
• Assess HPV triage as likely to be highly cost-effective compared with repeat cytology, and HPV test of cure as highly cost-effective because it reduces cytology workload while being slightly more effective at preventing cervical intraepithelial neoplasia grade 3 or worse.[3]

No total programme budget, tariff beyond the specified per-sample funding, long-term financing plan, quantified funding gap, or detailed economic assumptions are specified.[3][4]